Literature DB >> 1893123

Tumor-specific immunogenicity of stress-induced proteins: convergence of two evolutionary pathways of antigen presentation?

P K Srivastava1, M Heike.   

Abstract

Stress-induced proteins (hsps) elicit tumor-specific immunity to a number of murine tumors. Specificity of this immunity is puzzling in view of the fact that no tumor-specific DNA sequence polymorphisms have been identified in stress-induced genes, nor is there evidence for tumor-specific posttranslational modification of hsps. In this light, the possibility that hsps may not be antigenic per se, but may be carriers of antigenic moieties such as peptides, and may be accessory antigen-presenting molecules, is considered. A model where an hsp molecule such as gp96 acts as an intermediate in presentation of peptides to MHC is discussed and it is suggested that the hsp and MHC antigens are mediators of independent but functionally convergent phylogenetic pathways.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1893123

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  13 in total

Review 1.  Heat shock proteins: the fountainhead of innate and adaptive immune responses.

Authors:  S Basu; P K Srivastava
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

Review 2.  Molecular chaperones in the etiology and therapy of cancer.

Authors:  C Soti; P Csermely
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Endo-beta-D-glucuronidase (heparanase) activity of heat-shock protein/tumour rejection antigen gp96.

Authors:  P K Srivastava
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

4.  Molecular cloning and expression of a 70-kilodalton heat shock protein of Candida albicans.

Authors:  R La Valle; C Bromuro; L Ranucci; H M Muller; A Crisanti; A Cassone
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

Review 5.  Heat shock proteins transfer peptides during antigen processing and CTL priming.

Authors:  P K Srivastava; H Udono; N E Blachere; Z Li
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  Polyclonal T cell elimination by prolonged immunostimulation in an experimental model.

Authors:  F Galdiero; M Galdiero; I Nuzzo; M Vitiello; C Bentivoglio; C Romano-Carratelli
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

7.  Efficient cross-priming of antiviral CD8+ T cells by antigen donor cells is GRP94 independent.

Authors:  Avital Lev; Peniel Dimberu; Suman R Das; Jason C Maynard; Christopher V Nicchitta; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

Review 8.  A tale of two pities: autologous melanoma vaccines on the brink.

Authors:  David Berd
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

9.  Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.

Authors:  Gang Zhou; Zhengbin Lu; John D McCadden; Hyam I Levitsky; Aimee L Marson
Journal:  J Exp Med       Date:  2004-12-13       Impact factor: 14.307

10.  Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation.

Authors:  Z Li; P K Srivastava
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.